|
Market Closed –
|
5-day change | 1st Jan Change | ||
|
440.87 USD |
-1.68% | -3.20% | +9.48% | |
Published on 06/20/2025 at 21:55
Presenter Speech
Susie Lisa (Executives)
Thanks for your patience. Good evening, everyone. My name is Susie Lisa, and I’m the Senior Vice President of Investor Relations for Vertex Pharmaceuticals.
W
|
Vertex Pharmaceuticals Incorporated Presents at American Diabetes Association 85th Scientific Sessions, Jun-20-2025 07:15 PM |
09:55pm |
|
|
Morgan Stanley Adjusts Price Target on Vertex Pharmaceuticals to $460 From $464 |
Jun. 20 |
MT |
|
RBC Capital Adjusts PT on Vertex Pharmaceuticals to $420 From $423, Maintains Sector Perform Rating |
Jun. 17 |
MT |
|
Saudi Arabia Signs Multiple Healthcare Deals, Partnerships at BIO 2025 |
Jun. 17 |
MT |
|
Vertex Pharmaceuticals Incorporated Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 02:40 PM |
Jun. 10 |
|
|
Vertex Pharmaceuticals Exec Says Cystic Fibrosis Portfolio Has About 9% Exposure To Medicare And About 23% Exposure To Medicaid – Goldman Sachs Conference |
Jun. 10 |
RE |
|
Vertex Pharmaceuticals Incorporated Presents New Data on Benefits of ALYFTREK and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference |
Jun. 06 |
CI |
|
Vertex Pharmaceuticals Incorporated Presents at Bernstein 41st Annual Strategic Decisions Conference 2025, May-30-2025 08:00 AM |
May. 30 |
|
|
Eli Lilly to buy SiteOne for $1 billion with eye on non-opioid pain drug |
May. 27 |
RE |
|
Argus Adjusts Price Target on Vertex Pharmaceuticals to $525 From $550 |
May. 23 |
MT |
|
Vertex Pharmaceuticals Authorizes $4 Billion In Additional Share Repurchases |
May. 19 |
DJ |
|
Vertex Pharmaceuticals Inc – Authorizes $4 Billion Stock Repurchase Program – SEC Filing |
May. 19 |
RE |
|
S&P 500 Posts Weekly Decline as Health Care, Communication Services Drop |
May. 09 |
MT |
|
About Doves and Deals |
May. 07 |
 |
|
Analyst recommendations: Skechers, Doordash, Stellantis, The Trade Desk, Yeti Holdings… |
May. 07 |
|
|
Wolfe Research Downgrades Vertex Pharmaceuticals to Peer Perform From Outperform |
May. 07 |
MT |
|
Equities close lower as tariff uncertainty weighs |
May. 06 |
RE |
|
Equities close lower as tariff uncertainty weighs |
May. 06 |
RE |
|
Tranche Update on Vertex Pharmaceuticals Incorporated’s Equity Buyback Plan announced on February 7, 2023. |
May. 06 |
CI |
|
Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $621 From $617 |
May. 06 |
MT |
|
Barclays Adjusts Vertex Pharmaceuticals Price Target to $499 From $467, Maintains Equal Weight Rating |
May. 06 |
MT |
|
RBC Raises Price Target on Vertex Pharmaceuticals to $423 From $420, Keeps Sector Perform Rating |
May. 06 |
MT |
|
Morgan Stanley Lifts Price Target on Vertex Pharmaceuticals to $464 From $462, Keeps Equalweight Rating |
May. 06 |
MT |
|
Jefferies Adjusts Price Target on Vertex Pharmaceuticals to $575 From $550, Maintains Buy Rating |
May. 06 |
MT |
|
Morgan Stanley Adjusts Price Target on Vertex Pharmaceuticals to $464 From $462, Maintains Equalweight Rating |
May. 06 |
MT |
VRTX: Dynamic Chart
Quarterly revenue – Rate of surprise
Select your edition
All financial news and data tailored to specific country editions
